Semaglutide Win in HFpEF With Obesity Regardless of LVEF : v

Were the GLP-1 receptor agonist drug's apparent benefits in STEP-HFpEF due solely to weight loss or additional mechanisms? The trial offers a clue, experts say.

Related Keywords

Cleveland , Ohio , United States , United Kingdom , Dallas , Texas , Massachusetts , California , Boston , American , America , Bristol Myers Squibb , Greggc Fonarow , Muthiah Vaduganathan , Johnw Ostrominski , Coll Cardiol , Javed Butler , John Mcmurray , Baylor Scott , Los Angeles , Eli Lilly , University Of Glasgow , Boehringer Ingelheim , Heart Failure Society Of America , Astrazeneca , Tricog Health , Johnson , Novo Nordisk , White Research Institute , University Of Mississippi , Pfizer , University Of California , Novartis , Medtronic , Amgen , Harvard Medical School , Bayer Ag , Journal Of The American College Cardiology , Lexicon Pharmaceuticals , Heart Failure Society , Scientific Meeting , American College , Medical Center , American Regent , Applied Therapeutics , Cardiac Dimension , Element Science , Impulse Dynamics , Baxter Healthcare , Roche Diagnostics , Failure Society , Presented October , Heart Failure , Cardiovascular Imaging , Ardiac Imaging , V Imaging , Ejection Fraction Ef , Eft Ventricular Ejection Fraction Lvef , Obesity , Bese , Bariatric Surgery , Obesity Surgery , Weight Loss Surgery , Urgery Weight Loss , Glp 1 Receptor Agonists , Glucagon Like Peptide 1 Receptor Agonists , Weight Loss , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Weight Management , Receptor ,